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INTRODUCTION
Patients with mixed type Evans syndrome are very rarely
seen and it is difficult to manage them. Although mixed type
Evans syndrome may initially respond well to steroids, it usu-
ally runs a chronic course with intermittent exacerbations
(1, 2). Rituximab, a chimaeric monoclonal antibody against
CD20 that depletes B cells in the circulation and in lymphoid
tissues, has shown efficacy for the treatment of CD20-posi-
tive lymphoproliferative disorders. The pathogenetic mech-
anism of autoimmune cytopenias is complex and B cells play
a crucial role in the pathogenesis of these disorders so that
this agent Rituximab has also been used with good success
for patients with autoimmune disease, including immune
thrombocytopenic purpura, autoimmune hemolytic anemia
and the other types of immune disease (3-6). We report here
on a patient with the mixed type Evans syndrome who had
a prompt response to rituximab. 
CASE REPORT
In July 2004, a 46-yr-old Korean woman was diagnosed
with mixed type Evans syndrome following her hospital ad-
mission because of the symptomatic anemia, jaundice and
thrombocytopenia. The laboratory tests showed: Hemoglobin,
4.1 g/dL; reticulocytes, 12.6%; WBC, 3,030/ L; platelets,
89,000/ L; and elevated levels of indirect bilirubin (2.53
mg/dL) and lactic dehydrogenase (LDH; 1,499 IU/L). Her
initial direct antiglobulin test was positive for complement
(C3d) and IgG. In addition, the patient’s serum contained a
cold hemagglutinin that had high thermal amplitude. The
serologies for HIV, EBV, CMV, hepatitis B and C viruses, and
Mycoplasma pneumoniae were all negative. Rheumatoid factor,
antinuclear antibodies, anti-double stranded DNA antibod-
ies and lupus anticoagulant were undetectable. Prednisone
therapy was started at a dose of 1 mg/kg/day. The hemoglobin
level and platelet count rose to 11.7 g/dL and 356,000/ L,
respectively. Fifteen weeks later (December 2004), the pred-
nisone was tapered to a maintenance dose of 10 mg daily. She
relapsed with hemolytic anemia (5.9 g/dL) and thrombocy-
topenia (9,000/ L). Despite retreatment of high dose steroid,
she never achieved any response. Rituximab was started at the
dose of 375 mg/m2 once a week for a total of 4 doses, and this
was well-tolerated and it induced a normalization of hemo-
globin, bilirubin and LDH, as well as inducing a significant
platelet count increase. The hemoglobin increased to 13.2
g/dL on day 56 and the platelet count increased to 30,000/ L
by day 12 after the first rituximab infusion. She subsequently
entered a durable remission with her hemoglobin level in the
range of 13.2-14.7 g/dL and her platelet count in the range
of 32,000-42,000/ L; she has maintained this remission now
for 6 months (Fig. 1).
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A Patient with Mixed Type Evans Syndrome: Efficacy of Rituximab
Treatment
Mixed type Evans syndrome is a very rare hematologic disease. Although mixed
type Evans syndrome may initially respond well to steroids, this disease usually runs
a chronic course with intermittent exacerbations. We describe here a 46-yr-old female
with the steroid-refractory, mixed type Evans syndrome, and she had a prompt res-
ponse to rituximab. She was diagnosed as having the mixed type Evans syndrome
with the clinical features of symptomatic anemia, jaundice and thrombocytopenia.
Prednisone therapy was commenced and her hemoglobin and platelet level returned
to the normal. However, after 15 weeks, she relapsed with hemolytic anemia and
thrombocytopenia. We started rituximab at the dose of 375 mg/m
2 once weekly for
a total of 4 doses, which was well-tolerated and this induced the normalization of
hemoglobin, bilirubin and lactic dehydrogenase, and there was also a significant
increase of the platelet count.
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syndrome. Additional treatment modalities, including sple-
nectomy, intravenous immunoglobulin, vincristine or aza-
thioprine, are used for the steroid-resistant or relapsing cases.
However, these treatment options are often unsuccessful and
they may be associated with serious side effects (1, 2). Ritu-
ximab was approved for the treatment of B-cell lymphomas,
and this drug has emerged as a promising treatment for idio-
pathic thrombocytopenic purpura and autoimmune hemolyt-
ic anemia (AIHA), including Evans syndrome and mixed
AIHA. The response rates have ranged from 25% to 100%
(3). The administration of rituximab causes depletion of B
cells expressing the surface antigen CD20. The mechanism
of cellular killing is thought to be secondary to the antibody-
dependent cellular toxicity and complement activation. Sup-
pression of autoreactive B cells may explain the sustained res-
ponse attained when using rituximab for the treatment of
lymphomas and autoimmune diseases (3). In the three previ-
ous reports on rituximab treatment for the mixed type AIHA,
including one case of mixed type Evans syndrome, all the
patients had successful resolution of their hemolytic anemia
(4-6). Our patient responded promptly and had a sustained
response, and any rituximab related side effects were not
observed. 
In conclusion, a decision to initiate rituximab early in the
course of mixed AIHA with/without immune thrombocy-
topenia is a reasonable treatment option if the syndrome is
refractory to steroid treatment. 
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Fig. 1. Schematic representation of the platelet and hemoglobin level in the period from July 2004 until May 2005 (At December 16, 2004
the patient was relapsed). (A) Mixed Evans syndrome was diagnosed and successfully treated with prednisone. (B) After relapse, intra-
venous infusions of rituximab (375 mg/m
2) were given once weekly for 4 consecutive weeks. Until 6 months of rituximab therapy, the patient
was stable. Black arrows represent rituximab infusions.
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